
Biondvax Pharmaceuticals Ltd - ADR (NASDAQ:BVXV) shares are trading higher by 32.1% at $1.81 after the company announced it signed a definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody therapies.
BiondVax says the company is planning a rapid development path that leverages the company's expertise and capabilities in biological drug development and manufacturing. BiondVax notes that NanoAbs can be mass-produced through recombinant protein manufacturing in sites such as BiondVax's GMP biologics manufacturing facility in Jerusalem.